Micromedic

MicroMedicLOGO

We own approximately 46% of the issued and outstanding shares on a fully diluted basis of Micromedic.

Micromedic owns a pipeline of products and product candidates focusing on in vitro diagnostics of cancer, particularly the early detection, monitoring recurrence and identification of cancer and pre-cancer cells and assessing risks related to a treatment’s side effects. Micromedic’s principal product and product candidates are:

  • CellDetect, a platform technology that is used in a color differentiating diagnostic kit to stain and detect cancer and pre-cancer cells for several cancer indications, currently focusing on (i) the detection and monitoring of bladder cancer recurrence using urine samples, and (ii) the diagnosis of cervical cancer using cervical smears; and
  • BRONJ test, a predictive genetic test for identification of individuals with increased risk of developing bisphosphonate-related osteonecrosis of the jaw, or BRONJ.

The CellDetect Platform Technology

Micromedic’s CellDetect technology is a color differentiating diagnostic kit that can be used to stain and detect cancer and pre-cancer cells. While it has the potential to be used for several cancer indications, it is currently focused on detecting and diagnosing cervical cancer using smears and on monitoring bladder cancer recurrence using urine samples.

The test has no side effects or special risks and results are available within few hours. The kit uses materials and equipment available in standard pathological laboratories. The staining protocol is relatively short (less than 1.5 hours, including a one hour fixation procedure) and can be applied to existing automated systems. It has the potential to provide the cytologist with a unique, simple and efficient tool that combines color-based differentiation with morphological parameters for detecting and identifying different degrees of neoplasia.

Website: www.zetiq.co.il

BRONJ Test

Cancer and osteoporosis are driving a large number of bone-strengthening treatments. In the United States, more than 15 million prescriptions for oral or intravenous bisphosphonates, or BPs, are dispensed each year for the prevention and management of osteoporosis, and are also used to prevent bone complications in metastatic cancer. BRONJ is a severe side effect following treatment with BPs, which causes necrosis of the maxillary bone. This side effect, driven by the increase in prescribing BPs primarily for cancer and Osteonecrosis patients, most frequently appears in patients that are treated intravenously with BPs.

Micromedic is currently developing a predictive genetic (SNP) test for identification of individuals with increased risk of developing BRONJ, mainly among multiple myeloma patients.

Micromedic site: www.m-medic.com